CytomX Therapeutics (CTMX) Liabilities and Shareholders Equity (2014 - 2026)

CytomX Therapeutics has reported Liabilities and Shareholders Equity for 13 years, with the latest figure at $359.4 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 264.84% year-over-year to $359.4 million; the trailing twelve-month figure through Mar 2026 stood at $844.2 million (up 63.22% YoY), and the FY2025 full-year result was $151.6 million, up 25.75% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $359.4 million, up from $151.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $359.4 million in Q1 2026, with the low at $98.5 million in Q1 2025.
• Historically, Liabilities and Shareholders Equity has averaged $203.4 million across 5 years, with a median of $201.8 million in 2023.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity sank 46.67% — and 2026, when it jumped 264.84%.
• CytomX Therapeutics' Liabilities and Shareholders Equity stood at $260.9 million in 2022, then dropped by 22.65% to $201.8 million in 2023, then sank by 40.27% to $120.5 million in 2024, then increased by 25.75% to $151.6 million in 2025, then surged by 137.1% to $359.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $359.4 million (Q1 2026), $151.6 million (Q4 2025), and $158.3 million (Q3 2025), per Business Quant data.